



Tumor Immunology and Immunotherapy Resistance

Guest Editors:

Dr. Subbaya Subramanian

Department of Surgery,
University of Minnesota,
Minneapolis, MN 55455, USA

Dr. Timothy K. Starr

Department of Obstetrics,
Gynecology & Women's Health,
University of Minnesota,
Minneapolis, MN, USA

Dr. Xianda Zhao

Department of Surgery,
University of Minnesota,
Minneapolis, MN, USA

Deadline for manuscript
submissions:

closed (15 December 2022)

Message from the Guest Editors

Dear Colleagues,

Over the last decade, there has been an increasing understanding of molecular mechanisms that regulate anti-tumor immune responses and an exponential increase in the use of novel cancer immunotherapies in various cancer types. Despite the demonstrated success of tumor immunotherapy, most patients do not respond, and there is also a development of resistance mechanisms in patients who initially respond to immunotherapies. The scope of this Special Issue aims to cover current knowledge, cutting-edge technologies, and prospects in tumor immunology and immunotherapies. We hope that the research and review articles in this Special Issue will provide valuable references for developing next-generation cancer immunotherapies.

Dr. Subbaya Subramanian

Dr. Timothy K. Starr

Dr. Xianda Zhao

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)